Effective with Amendment 15, eligible participants who were allocated to the Active Comparator arm and experienced disease progression will be provided with the opportunity to crossover to receive pembrolizumab 200 mg one time every three weeks (Q3W) for up to two years of treatment in the Crossover Phase of the study.